Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Maintenance Therapy in Post-transplant AML
NCT07304232Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2025; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07304232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304232.